Continuous glucose monitoring in type 2 diabetes: Evidence for glycaemic metrics and patient‐reported outcomes
Authors' conclusion
CGM use was associated with clinically meaningful improvements in glycaemic metrics and PROs in adults with T2D.
Study context
- Population
- Adults with T2D
- Participants
- ≈ 3,275 adults30 studies
- Comparison
- Continuous glucose monitoring (CGM) use
- Outcome
- Glycaemic measures and PROs
Methodological detailsPubMed, Scopus, Cochrane Library and CINAHL searched from inception to June 2025, RCTs and non-randomised studies including quasi-experimental and observational designs
- PubMed, Scopus, Cochrane Library and CINAHL searched from inception to June 2025
- RCTs and non-randomised studies including quasi-experimental and observational designs
Pooled result
As reported in the abstract
- CGM use associated with improvement in HbA1c, particularly in insulin-treated individuals and those with higher baseline HbA1c
- CGM use increased TIR by ≈9-15 percentage points (1.5-3.6 h/day)
- CGM generally associated with reduced hypoglycaemia risk and glycaemic variability; effects on hypoglycaemia not uniform
- Diabetes-specific patient-reported outcomes (PROs) (treatment satisfaction, diabetes-related distress) showed more consistent improvement
- Changes in overall quality-of-life measures less pronounced
Original publication
Continuous glucose monitoring in type 2 diabetes: Evidence for glycaemic metrics and patient‐reported outcomes. Diabet Med. Published 18 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →